BIGMAR Inc Receives Suitability
Selected Abstract
BIGMAR, Inc. Receives Suitability Petition Approval from FDA to File ANDA for Dacarbazine.
JOHNSTOWN, Ohio, Dec. 7 /PRNewswire/ -- BIGMAR, INC. (Nasdaq: BGMR; BSE: BGM) announced today that it has received approval of a Suitability Petition by the United States Food and Drug Administration ( FDA ) on November 30, 1998, which permits the filing of an Abbreviated New Drug Application ( ... December 7, 1998; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
BIGMAR, Inc. Receives Suitability Petition Approval from FDA to File ANDA for Dacarbazine.
2.
BIGMAR, Inc. Receives Suitability Petition Approval From FDA to File ANDA for Dacarbazine.
3.
Bigmar, Inc. Receives Suitability Petition Approval From FDA to File ANDA for Methotrexate for Injection, 500 Mg.
|
